Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion

Vader, Maartje J.C.; Schauwvlieghe, A.M.E.; Verbraak, Frank D.; Dijkman, Greet; Hooymans, Johanna M. M.; Los, Leonoor I.; Zwinderman, Aeilko H.; Hoyng, Carel B.; Leeuwen, Redmer van; Vingerling, Johannes R.; Jong‐Hesse, Yvonne de; Lith-Verhoeven, Janneke J.C. van; Dijkgraaf, Marcel G. W.; Schlingemann, Reinier O.

doi:10.1016/j.oret.2019.12.019

Cited by 20 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the perspective of various biochemical compatibility, biochemical degradability, and safety of this nanomaterial, PCL can be almost completely degraded in the body, and the products after degradation are mainly gaseous carbon dioxide and concentrated ammonia, which will not directly interfere with the normal various physiological and chemical activities of human cells have three major advantages such as complete biochemical degradation and good biochemical compatibility. It is one of the raw materials of the U.S. Food and Drug Administration (FDA) nationally approved products that can be used in pharmaceuticals (18)(19).…”

Section: Selection Of Nanoparticle Materialsmentioning

confidence: 99%

Recombinant Plasminogen Activator Modified Nanoparticles for Targeting Thrombolysis in Branch Retinal Vein Occlusion

Zhang¹,

Han²,

Zhang³

et al. 2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Branch Retinal Vein Occlusion (BRVO) is the second chronic branch retinal vascular disease that causes abnormal vision loss after acute branch retinal disease in type 2 diabetes. There is no scientific conclusion about its specific pathogenic mechanism at present. Most clinical scholars generally support the theory that the partial human anatomical structure and various systemic risk psychological factors cause insufficient oxygen supply and hemostasis in the local branch retinal arteries. The research results of this article aim to reconstruct a non-nanocell-targeted thrombolytic drug delivery system without modification of rtPA without polyethylene glycol-methyl polycaprolactone and to re-evaluate its thrombus targeting and dissolution. The effect and safety of thrombus provide a new strategy for realizing combined treatment of thrombus. It is a study on the targeting of rtPA-NP to thrombus and its thrombolytic properties. HPLC method was used to detect the binding of fibrin clot prepared in vitro with coumarin-6 labeled NP and rtPA-NP; immunofluorescence technique was used to observe the location of nanomedicine and fibrin clot in branch retinal vein occlusion model Condition. The rtPA-NP drug delivery system constructed in this study not only retains the activity of rtPA and good thrombus targeting but also significantly prolongs its half-life and simplifies the way of administration. The therapeutic efficiency of rtPA-NP thrombus targeted administration on branch retinal vein occlusion reached 85.64%. The successful construction of the rtPA-NP thrombus targeted drug delivery system provides a new way for thrombosis treatment and lays the foundation for the future combination of anticoagulants and vascular protection drugs to achieve the combined treatment of thrombosis and the development of safe and efficient thrombolytic drugs.

show abstract

Section: Selection Of Nanoparticle Materialsmentioning

confidence: 99%

Recombinant Plasminogen Activator Modified Nanoparticles for Targeting Thrombolysis in Branch Retinal Vein Occlusion

Zhang¹,

Han²,

Zhang³

et al. 2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

show abstract

“…Bevacizumab is as effective as Ranibizumab in the treatment of macular edema secondary to retinal vein occlusion. 10 According to Tanzanite study, 5 simultaneous same day Aflibercept and suprachoroidal triamcinolone acetonide, reduced the number of injections after 3 months in patients with macular edema associated with retinal vein occlusion. Macular edema resolved in 87.0% after one month, 87.0% after 2 months and 78.3% after 3 months in the combination arm, vs. 56.5% after 1 month, 47.8% after 2 months and 47.8% after 3 months in the Aflibercept arm.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of Intravitreal Bevacizumab Combined with Suprachoroidal Triamcinolone Acetonide in Central Retinal Vein Occlusion with Macular Edema

Salahuddin¹,

Jan²,

Mahsood³

et al. 2023

pak J Ophthalmol

View full text Add to dashboard Cite

Purpose: To determine the outcomes of intravitreal Bevacizumab 1.25 mg in 0.05 ml combined with supra-choroidal triamcinolone acetonide 0.05 ml in terms of safety and efficacy, while treating macular edema associated with central retinal vein occlusion (CRVO). Study Design: Interventional case series. Place and Duration of Study: This study was conducted at ophthalmology department of Hayatabad medical complex, Peshawar from July 2021 to December 2021. Methods: Total 34 patients of CRVO with macular edema were included in the study. After complete ocular examination each patient received one injection of intravitreal bevacizumab (1.25 mg/0.05 ml) along with supra-choroidal triamcinolone acetonide (2 mg/0.05 ml), followed by similar monthly injections for two months. Visual acuity and central macular thickness and intra-ocular pressure (IOP) were assessed at presentation and then monthly for 3 months. Visual acuity was measured in Log-MAR, central foveal thickness on SD-OCT and IOP was measured with Goldmann Applanation Tonometer. The data was analyzed using SPSS version 24. For comparison of means, the paired-t test was used. A significance level of <0.05 was set for significance. Results: There were 22 (64.7%) males and 12 (35.5%) females. Mean age of the patients was 53.18 ± 13.39 years. Central foveal thickness decreased significantly at 3 months post treatment (p ˂ 0.001). Visual acuity also significantly increased from presentation to 3rd month post treatment (p ˂ 0.001), and the intra-ocular pressure remained within normal range from presentation to 3rd month post treatment. Conclusion: Both supra-choroidal triamcinolone acetonide and intravitreal bevacizumab are safe and effective in the treatment of macular edema secondary to CRVO.

show abstract

“…In hemiretinal vein occlusion, signs are restricted to the superior or inferior half of the retina. 1 In branch retinal vein occlusion (BRVO), occlusion tends to occur at an arteriovenous crossing with haemorrhages localised to the area drained by the branch retinal vein. 2 CRVO is less common than BRVO with a reported prevalence of 0.1%-0.4%.…”

Section: Introductionmentioning

confidence: 99%

Management of macular oedema due to retinal vein occlusion: An evidence‐based systematic review and meta‐analysis

Cornish

Zagora

Spooner³

et al. 2023

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Background Central retinal vein occlusion and branch retinal vein occlusion are common causes of visual loss due to associated macular oedema. The aim of this review was to assess the effectiveness of interventions improving vision and treating macular oedema in central retinal vein occlusion and branch retinal vein occlusion. Methods Medical search engines and clinical trial registries were systematically searched. Randomised clinical trials with ≥90 eyes and real‐world outcome studies with ≥100 eyes each with ≥6 months follow‐up were included. Results There were 11 randomised controlled trials evaluating treatments for central retinal vein occlusion which met the inclusion criteria and 10 for branch retinal vein occlusion. There were 10 real world outcome studies of central retinal vein occlusion and 5 real world outcome studies of branch retinal vein occlusion. Meta‐analysis was performed on studies that met the defined inclusion criteria. Main outcomes were change in visual acuity at 6‐, 12‐, 24‐ and 36 months by treatment. Conclusions Intravitreal anti‐vascular endothelial derived growth factor is recommended as first line treatment over intravitreal corticosteroid due to its effectiveness and lower rate of ocular adverse events. Best outcomes are achieved when intravitreal treatment is started early. Macular laser may have an adjunctive role in branch retina vein occlusion but not central retinal vein occlusion.

show abstract

Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion

Cited by 20 publications

References 29 publications

Recombinant Plasminogen Activator Modified Nanoparticles for Targeting Thrombolysis in Branch Retinal Vein Occlusion

Recombinant Plasminogen Activator Modified Nanoparticles for Targeting Thrombolysis in Branch Retinal Vein Occlusion

Outcomes of Intravitreal Bevacizumab Combined with Suprachoroidal Triamcinolone Acetonide in Central Retinal Vein Occlusion with Macular Edema

Management of macular oedema due to retinal vein occlusion: An evidence‐based systematic review and meta‐analysis

Contact Info

Product

Resources

About